Rituximab plus VRD, then lenalidomide to treat Waldenstrom’s
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 study tests a treatment plan that starts with rituximab plus VRD (bortezomib, and reduced-dose drugs in the VRD group), then uses lenalidomide for maintenance to help control Waldenstrom’s macroglobulinemia. It may help people who need treatment because their disease is measurable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Waldenstrom’s macroglobulinemia
- You’re an adult (19 or older) and able to follow oral and written study instructions
- Your general health is good enough for study treatment (ECOG 0–2)
- Your disease must be measurable, with IgM higher than 0.5 g/dL
- Your blood counts and organ function (bone marrow, liver, kidneys) meet the study lab ranges
- You can safely use contraception as required (including ongoing birth control for after treatment)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two starting treatment plans for Waldenström’s macroglobulinaemia, testing whether one works better or causes fewer problems. It studies rituximab plus ibrutinib versus a standard mix of rituximab, cyclophosphamide, and dexamethasone (steroids).
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This Phase 2 study tests whether the combination of venetoclax and rituximab works better for Waldenström’s macroglobulinemia (WM) than expected from standard approaches. It is for adults with WM who have symptoms or organ/health problems caused by the disease.
This trial tests a combination of three drugs (nemtabrutinib, bortezomib, and rituximab) for people with Waldenstrom's macroglobulinemia (a rare blood cancer) who have not yet had treatment. It aims to see if the combination is safe and effective.
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
Hear when a new Waldenström's Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.